1Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 muta- tion carriers [ J ]. J Natl Cancer Inst, 1999, 91 ( 17 ) 1475 - 1479.
2Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers [ J ]. J Clin Oncol, 2000, 18 ( Suppl 21 ) : 100S - 103S.
3Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation [ J ]. N Engl J Med, 2002,346 (21) : 1609 - 1615.
4Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylac- tic oophorectomy in carriers of BRCA1 or BRCA2 muta- tions[J]. N Engl J Med,2002,6(21) :1616 - 1622.
5Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer:a multi-center, prospective study [ J ]. J Clin Oncol, 2008,26 ( 8 ) : 1331 - 1337.
6Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk fol- lowing bilateral oophorectomy in BRCA1 and BRCA2 mu- tation cmTiers : an international case-control study [ J ]. J Clin Oncol, 2005,23 (30) : 7491 - 7496.
7Domchek SM,Friebel TM,Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation car- riers with cancer risk and mortality [ J ] JAMA, 2010,304 (9) :967 -975.
8Mclanghlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy:trends in use from 1995 through 20051 J ]. Cancer, 2009,115 ( 23 ) : 5404 - 5412.
9Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment[J]. J Clin Onco1,2007,25 ( 33 ) :5203 - 5209.
10Kurian AW,Lichtensztajn DY, Keegan TH, et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998 - 2011 [ J ]. JAMA,2014,312 (9) :902 - 914.
